U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07210749) titled 'Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma' on Sept. 22.
Brief Summary: Current standard RT doses (24-25Gy) provide excellent disease control for patients with indolent B-cell orbital lymphoma, but can cause significant late toxicities. Ultra-low dose RT (4Gy in 2 fractions) has minimal toxicity but lower disease control, requiring intensive follow-up to salvage persistent tumors. Some centers are moving towards this dose as the new standard. A recent study using 12Gy in 4 fractions to any body site showed early data suggesting high disease control rates with minimal toxicity. This study assesses 12Gy in 6 fractions, aimin...